Luvesilocin

Chemical compound From Wikipedia, the free encyclopedia

Luvesilocin, also known as RE104 and FT-104, as well as 4-glutaryloxy-N,N-diisopropyltryptamine (4-HO-DiPT O-glutarate or 4-GO-DiPT), is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families which is under development for the treatment of psychiatric disorders.[3][4] It is taken orally or by subcutaneous injection.[3][2]

Other namesRE-104; RE104; FT-104; FT104; 4-Glutaryloxy-N,N-diisopropyltryptamine; 4-Hydroxy-N,N-diisopropyltryptamine O-glutarate; O-Glutaryl-4-hydroxy-N,N-diisopropyltryptamine; 4-HO-DiPT glutarate; O-Glutaryl-4-HO-DiPT; 4-GO-DiPT
Routes of
administrationOral, subcutaneous injection[1][2]
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Quick facts Clinical data, Other names ...
Luvesilocin
Clinical data
Other namesRE-104; RE104; FT-104; FT104; 4-Glutaryloxy-N,N-diisopropyltryptamine; 4-Hydroxy-N,N-diisopropyltryptamine O-glutarate; O-Glutaryl-4-hydroxy-N,N-diisopropyltryptamine; 4-HO-DiPT glutarate; O-Glutaryl-4-HO-DiPT; 4-GO-DiPT
Routes of
administration		Oral, subcutaneous injection[1][2]
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Metabolites• 4-HO-DiPT[2]
Onset of action≤1 hour (s.c.Tooltip subcutaneous injection)[2]
Elimination half-life• Luvesilocin: 0.43–0.64 hours (s.c.Tooltip subcutaneous injection)[1][2]
• 4-HO-DiPT: 2.7–4.1 hours (s.c.Tooltip subcutaneous injection)[1][2]
Duration of action3.6 hours (range ~3–4 hours) (s.c.Tooltip subcutaneous injection)[1][2]
Identifiers
  • 1-[3-[2-[Bis(1-methylethyl)amino]ethyl]-1H-indol-4-yl] pentanedioate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H30N2O
Molar mass326.484 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC1=CNC2=C1C(=CC=C2)OC(=O)CCCC(=O)O)C(C)C
  • InChI=1S/C21H30N2O4/c1-14(2)23(15(3)4)12-11-16-13-22-17-7-5-8-18(21(16)17)27-20(26)10-6-9-19(24)25/h5,7-8,13-15,22H,6,9-12H2,1-4H3,(H,24,25)
  • Key:LSDOIAGGRBGDJJ-UHFFFAOYSA-N
Close

The drug is a prodrug ester of 4-HO-DiPT, which acts as a non-selective serotonin receptor agonist including of the serotonin 5-HT2A receptor.[5][6]

Luvesilocin was first described in the literature in 2021.[5][7] It is under development for the treatment of postpartum depression and treatment-resistant depression.[8][9][10][11] As of September 2025, the drug has reached phase 2 clinical trials.[12] A phase 3 trial is planned for 2026.[12]

Use and effects

See also: 4-HO-DiPT § Use and effects
Luvesilocin (RE104; 4-GO-DiPT) Drug Effects Questionnaire (DEQ) "feel high" ratings at doses of 5 to 40 mg via subcutaneous injection over 6 hours.[2]

The effects of luvesilocin have been clinically studied.[2] It was evaluated at doses of 5 to 40 mg (equivalent to ~4–32 mg 4-HO-DiPT) by subcutaneous injection in this study.[2] The drug was specifically assessed in terms of modified Drug Effects Questionnaire (DEQ) ratings, Mystical Experience Questionnaire (MEQ) ratings, and adverse effects.[2] The mean duration of the psychedelic experience after administration of luvesilocin at a dose of 30 mg was found to be 3.6 hours.[2][1]

Interactions

See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

Pharmacodynamics

Luvesilocin is a prodrug that is metabolized into 4-HO-DiPT.[13][14] This metabolite is an analogue of the neurotransmitter serotonin and acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor.[5][6] Activation of the serotonin 5-HT2A receptor is thought to be specifically responsible for the hallucinogenic effects of serotonergic psychedelics.[citation needed]

4-HO-DiPT produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[15] In drug discrimination tests, 4-HO-DiPT fully substituted for the psychedelic drug DOM, with 5-fold lower potency than DOM and 2-fold lower potency than psilocin (4-HO-DMT).[16]

The drug activates basolateral amygdala (BLA) interneurons via the serotonin 5-HT2A receptor to enhance GABAergic inhibition of principal neurons in the BLA, which may mediate an anxiolytic effect of suppression of learned fear (fear extinction) in rodents.[5][6]

Pharmacokinetics

Given by subcutaneous injection, the elimination half-life of luvesilocin is 0.43 to 0.64 hours and of 4-HO-DiPT is 2.7 to 4.1 hours.[2] The mean duration with this route at the employed dose was 3.6 hours.[2]

Chemistry

Synthesis

The chemical synthesis of luvesilocin has been described.[13]

Analogues

Analogues of luvesilocin include 4-HO-DiPT (iprocin), 4-AcO-DiPT (ipracetin), 4-PrO-DiPT, 4-AcO-DMT (psilacetin), 4-PrO-DMT, and 4-GO-DMT (RE-109), among others.

History

Luvesilocin was first described in the literature in 2021.[5][7]

Society and culture

Names

Luvesilocin is the generic name of the drug and its INNTooltip International Nonproprietary Name.[17] It is also known by its developmental code names RE104 or RE-104 and FT104 or FT-104.[3]

Canada

Luvesilocin is not a controlled substance in Canada as of 2025.[18]

United States

Luvesilocin is not an explicitly controlled substance in the United States.[19] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

Research

Luvesilocin is under development for the treatment of postpartum depression (PPD), treatment-resistant depression, and other psychiatric disorders.[3][1][20][21] As of September 2025, it has reached phase 2 clinical trials for these indications.[12] A phase 3 trial is planned for 2026.[12] The drug is being developed by Reunion Neuroscience (formerly known as Field Trip Health).[3]

See also

References

External links

Related Articles

Wikiwand AI